Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Marksans Pharma gets USFDA nod for acid reflux drug
Reinforcing commitment to ethical and sustainable growth
The agreement complements other PPAs for Sandoz production sites globally
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Subscribe To Our Newsletter & Stay Updated